Phio Pharmaceuticals Corp.
NASDAQTotal Valuation
Phio Pharmaceuticals Corp. carries a market capitalization of 13.13M, placing it among publicly traded companies globally. Its enterprise value stands at -8.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.13M |
| Enterprise Value | -8.13M |
Share Statistics
Phio Pharmaceuticals Corp. currently has 11.62M shares outstanding.
| Shares Outstanding | 11.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.06 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | -0.83 |
| P/OCF Ratio | -0.83 |
Financial Position
Phio Pharmaceuticals Corp. maintains a current ratio of 18.32, meaning it holds 18.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 18.32 |
| Quick Ratio | 17.93 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -70.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Phio Pharmaceuticals Corp.'s stock has declined approximately -52.71967% over the past 52 weeks. The 50-day moving average sits at 1.06, while the 200-day moving average is 1.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | -52.71967% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.27 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.51M, while operating income came in at -11.51M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.51M |
| Pretax Income | -10.93M |
| Net Income | -10.93M |
| EBITDA | -11.51M |
| EBIT | -11.51M |
| Earnings Per Share (EPS) | -1.50 |
Balance Sheet
Total book value stands at -159.06M, with working capital of 16.45M providing operational flexibility.
| Cash & Cash Equivalents | 17.03M |
| Total Debt | N/A |
| Net Debt | -17.03M |
| Equity (Book Value) | -159.06M |
| Book Value Per Share | -21.81 |
| Working Capital | 16.45M |
Cash Flow
Phio Pharmaceuticals Corp. produced -10.71M in operating cash flow over the past twelve months. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -10.72M - equivalent to -1.47 per share.
| Operating Cash Flow | -10.71M |
| Capital Expenditures | -10,000.00 |
| Free Cash Flow | -10.72M |
| FCF Per Share | -1.47 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -162.58 |
| FCF Yield | -120.22 |
Stock Splits
Phio Pharmaceuticals Corp.'s most recent stock split took place on July 5, 2024 with a 9:1 split ratio.
| Last Split Date | 7/5/2024 |
| Split Ratio | 9:1 |
Scores
Phio Pharmaceuticals Corp. posts an Altman Z-Score of -8.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.22 |